Werewolf Therapeutics Inc (HOWL)

[Monksdream]

HOWL under $2

[tw0122]

Halloween is here again give it another howl. Flip time coming $4.45

[tw0122]

$3.65 + 30% HOWLing a little some.. Title: INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models
Abstract Number: 955
Session Date and Time: Friday, Nov. 8, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

Title: The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study
Abstract Number: 672
Session Date and Time: Saturday, Nov. 9, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf leverages its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. The Company’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 as a single agent in multiple tumor types and Non-Hodgkin Lymphoma. To learn more visit www.werewolftx.com.

WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

[Monksdream]

HOWL under $3

[Monksdream]

HOWL under $3

[Monksdream]

HOWL under $10

[Monksdream]

HOWL new 52 week high

[Pt3]

Yea your gap and trapped make me buy caud instead of this

[TheFinalCD]

HOWL todays algo patented Gap & Trap on Phase #1 news

[TheFinalCD]

Werewolf Therapeutics soars 52% premarket after presentsing preliminary monotherapy data from Phase 1/1b clinical trial establishing proof of mechanism for WTX-124$HOWL#AInvest #Ainvest_Wire #trade #source #wallstreet
View more: https://t.co/aTzfU7GqUS pic.twitter.com/rClSWzl2IS

— AInvest Wire (@Ainvest_Wire) November 3, 2023

[TheFinalCD]

$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL

[tw0122]

$3 + otw Halloween is here give it a HOWL

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2

[The Night Stalker]

dip

[The Night Stalker]

dip

[The Night Stalker]

watching

[The Night Stalker]

soon

[The Night Stalker]

insert dd

[The Night Stalker]

can be big

[The Night Stalker]

wow

[The Night Stalker]

wow

[The Night Stalker]

hold

[The Night Stalker]

slow

[The Night Stalker]

slow

[The Night Stalker]

agreed

[The Night Stalker]

like thiks

[The Night Stalker]

off radar

[The Night Stalker]

catchy name

[The Night Stalker]

catchy name

[surf1944]

https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion

[Mr. Zen]

Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

“These promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. “This morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”

[makinezmoney]

$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL

[Makk1]

Good call here, looking very good

[makinezmoney]

$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL

[bobbo5]

I agree and it looks like share price has been moving up this past week

[dia76ca]

Very interesting company. I like it's chances.